Gastrointestinal Very common (10% or more): Gastrointestinal adverse reactions (up to 73%), nausea (up to 44%), vomiting (up to 36%), diarrhea (up to 30%), constipation (up to 24.2%), abdominal pain (up to 20%) Common (1% to 10%): Dyspepsia, abdominal distension, eructation, flatulence, gastroenteritis, gastroesophageal reflux disease, gastritis, viral gastroenteritis, increased amylase, increased lipase, dry mouth, severe gastrointestinal adverse reactions, delayed gastric emptying Uncommon (0.1% to 1%): Acute pancreatitis, appendicitis Frequency not reported : Hemorrhoids, hiccups Postmarketing reports : Ileus, intestinal obstruction, severe constipation, hiccups, acute pancreatitis, necrotizing pancreatitis In clinical trials in adults using the subcutaneous injection for weight reduction, 73% of treated patients reported gastrointestinal adverse reactions, including severe reactions (4.1%)
Novo Nordisk declined to explain the timing of these submissions, but a spokesperson said the company is committed to addressing all the reporting issues found during last years FDA inspection of Novo Nordisk facilities and mentioned again in this new warning letter
Mochi's billing has drawn complaints about surprise membership charges, so review the fee schedule closely before signing up with either provider
Ayuda a la prdida de peso desde la prevencin de trastornos alimenticios , puesto que, acompaa en el proceso de prdida de peso detectando y abordando comportamientos y pensamientos que puedan llevar a trastornos alimenticios, para que la prdida de peso sea un proceso beneficioso para la salud fsica pero tambin para la salud mental
Protect WEGOVY injection from light
